Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can remote exercise and weight loss boost heart failure Patients' stamina?

NCT ID NCT07223242

Symptom relief Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a tailored, home-based exercise program (with or without weight loss medications) can improve exercise capacity and quality of life in 120 adults with heart failure with preserved ejection fraction (HFpEF). Participants will follow exercise videos and meet weekly with a coach. The goal is to find a practical, accessible way to help people with HFpEF feel better and be more active.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise training (moderate-intensity continuous training and resistance training) and weight loss medications (semaglutide or tirzepatide)
What this could lead to
If successful, this could offer a practical, home-based exercise program to help people with HFpEF feel better, move more easily, and improve their daily life.
What could go wrong
This is a mid-stage trial with only 120 participants, so results may not apply to everyone. The exercise program is remote, so adherence and effectiveness may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age\>= 18 yrs 2. LVEF (Left Ventricular Ejection Fraction) \>= 50% 3. History of HFpEF or at risk of HFpEF 1. HFpEF diagnosis based on:- -HF hospitalization within 12 months- * NT-proBNP \>360 pg/mL 2. Risk of HFpEF based on:- * \>2 risk factors (h/o diabetes, hypertension, obesity, physical inactivity by self-report) 4. SPPB \< 10 or VO2\<60th percentile 5. BMI \>=28 (for randomization in phase II) 6. Able to use cell phone and mobile application Exclusion Criteria: 1. Hospitalization 1 month prior to baseline visit 2. History of recurrent falls 3. eGFR (Estimated Glomerular Filtration Rate) \<20ml/min/1.73m 4. Active changes in HF therapies over 2 weeks prior to baseline visit 5. Inability participate in exercise training therapy 6. Inability to perform CPET (Cardiopulmonary Exercise Testing) testing 7. Severe left side valvular heart disease 8. End stage pulmonary disease, requiring continuous supplemental oxygen 9. Major surgery within 3 months of screening or major elective surgery during the duration of the study. 10. Unstable weight defined by \>5% change in body weight in last 30 days before first study visit. 11. Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic cardiomyopathies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Diabetic Cardiomyopathies diastolic heart failure Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic cardiomyopathies Hfpef - heart failure with preserved ejection fraction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.